Lung cancer · How outcomes have changed
Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020
| Design | Prospective multicentre cohort with historical comparison cohorts |
|---|---|
| Treatment | Care as delivered in 2020, including targeted therapy and immunotherapy |
| Control | Cohorts diagnosed in 2000 and 2010 |
| Population | 5015 patients with lung adenocarcinoma in non-academic public hospitals in France |
| Follow-up | 3 years |
| Primary endpoint | Three-year overall survival |
| Result | Three-year overall survival in the 2020 cohort was 38.6%, ranging from 21.3% in metastatic disease at diagnosis to 84.0% in stage I. Survival improved across the twenty years, and targeted therapy and immunotherapy were associated with longer survival in metastatic disease. |
| Secondary endpoints | Survival by stage, association with targeted therapy and immunotherapy |
Improvements in the OS of patients with lung adenocarcinoma were seen over 20 years in this setting of nonacademic public hospitals in France. Targeted therapy and immunotherapy were associated with longer OS among patients with metastatic disease.
The trial authors, in the published abstract
Real-world confirmation, in ordinary public hospitals rather than academic centres, that the trial-era gains in lung cancer have actually reached patients. The 21.3% three-year survival in metastatic disease would have been unthinkable in 2000 — and remains a long way from good.
Debieuvre D, Falchero L, Molinier O, et al. Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. NEJM Evid 2025 Jul;4(7):EVIDoa2400443.